TWI539959B - 治療轉移階段攝護腺癌的方法 - Google Patents
治療轉移階段攝護腺癌的方法 Download PDFInfo
- Publication number
- TWI539959B TWI539959B TW098104073A TW98104073A TWI539959B TW I539959 B TWI539959 B TW I539959B TW 098104073 A TW098104073 A TW 098104073A TW 98104073 A TW98104073 A TW 98104073A TW I539959 B TWI539959 B TW I539959B
- Authority
- TW
- Taiwan
- Prior art keywords
- degarelix
- treatment
- prostate cancer
- level
- individual
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims description 116
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 116
- 206010027476 Metastases Diseases 0.000 title claims description 22
- 230000009401 metastasis Effects 0.000 title claims description 20
- 238000000034 method Methods 0.000 title description 54
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 233
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims description 218
- 229960002272 degarelix Drugs 0.000 claims description 218
- 238000011282 treatment Methods 0.000 claims description 137
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 68
- 230000001394 metastastic effect Effects 0.000 claims description 62
- 210000002966 serum Anatomy 0.000 claims description 42
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 33
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 33
- 238000012423 maintenance Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 21
- 102000001554 Hemoglobins Human genes 0.000 claims description 18
- 108010054147 Hemoglobins Proteins 0.000 claims description 18
- 239000003098 androgen Substances 0.000 claims description 15
- 210000002307 prostate Anatomy 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 122
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 122
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 102
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 88
- 108010000817 Leuprolide Proteins 0.000 description 68
- 229960004338 leuprorelin Drugs 0.000 description 68
- 229960003604 testosterone Drugs 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 31
- 102000009151 Luteinizing Hormone Human genes 0.000 description 30
- 108010073521 Luteinizing Hormone Proteins 0.000 description 30
- 229940040129 luteinizing hormone Drugs 0.000 description 30
- 230000001225 therapeutic effect Effects 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 19
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 18
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 18
- 229940028334 follicle stimulating hormone Drugs 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 239000002585 base Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 102000008238 LHRH Receptors Human genes 0.000 description 13
- 108010021290 LHRH Receptors Proteins 0.000 description 13
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 12
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 12
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000002474 gonadorelin antagonist Substances 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 11
- 239000005556 hormone Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000007774 longterm Effects 0.000 description 11
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 11
- 238000012216 screening Methods 0.000 description 10
- 230000002280 anti-androgenic effect Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000000051 antiandrogen Substances 0.000 description 8
- 230000005713 exacerbation Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010006002 Bone pain Diseases 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 206010027452 Metastases to bone Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 3
- 208000033830 Hot Flashes Diseases 0.000 description 3
- 206010060800 Hot flush Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010066901 Treatment failure Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 229960000997 bicalutamide Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011471 prostatectomy Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000011446 adjuvant hormonal therapy Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010036697 Primary hypothyroidism Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039840 Secondary hypothyroidism Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010070822 acyline Proteins 0.000 description 1
- ZWNUQDJANZGVFO-YHSALVGYSA-N acyline Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(C)=O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(C)=O)C=C1 ZWNUQDJANZGVFO-YHSALVGYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- -1 amino-substituted phenylalanine side chain Chemical group 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 229940127233 azaline B Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000029305 central congenital hypothyroidism Diseases 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960000377 degarelix acetate Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 108010083551 iturelix Proteins 0.000 description 1
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2774108P | 2008-02-11 | 2008-02-11 | |
| EP08250703 | 2008-02-29 | ||
| US14795609P | 2009-01-28 | 2009-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200938217A TW200938217A (en) | 2009-09-16 |
| TWI539959B true TWI539959B (zh) | 2016-07-01 |
Family
ID=39718285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098104073A TWI539959B (zh) | 2008-02-11 | 2009-02-09 | 治療轉移階段攝護腺癌的方法 |
| TW098104075A TWI442932B (zh) | 2008-02-11 | 2009-02-09 | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098104075A TWI442932B (zh) | 2008-02-11 | 2009-02-09 | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (17) | US20090203623A1 (https=) |
| EP (7) | EP2650012B1 (https=) |
| JP (12) | JP5924866B2 (https=) |
| KR (8) | KR20220009504A (https=) |
| CN (4) | CN101998861A (https=) |
| AU (2) | AU2009213751B2 (https=) |
| BR (2) | BRPI0908127A2 (https=) |
| CA (3) | CA2714445C (https=) |
| CY (3) | CY1115561T1 (https=) |
| DK (3) | DK2505204T3 (https=) |
| EA (4) | EA017582B1 (https=) |
| ES (3) | ES2532709T3 (https=) |
| HK (1) | HK1198243A1 (https=) |
| HR (3) | HRP20140665T1 (https=) |
| IL (3) | IL207295A (https=) |
| JO (1) | JOP20090061B1 (https=) |
| MX (2) | MX2010008817A (https=) |
| NZ (4) | NZ587057A (https=) |
| PL (3) | PL2505204T3 (https=) |
| PT (3) | PT2650012E (https=) |
| RU (2) | RU2504393C2 (https=) |
| SI (3) | SI2249859T1 (https=) |
| TW (2) | TWI539959B (https=) |
| WO (2) | WO2009101533A1 (https=) |
| ZA (1) | ZA201005697B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| JO3525B1 (ar) * | 2008-02-11 | 2020-07-05 | Ferring Int Center Sa | علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس |
| TWI539959B (zh) * | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| MX2011011431A (es) * | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| FR2964323B1 (fr) * | 2010-09-08 | 2012-11-09 | Jean Pierre Raynaud | Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| AU2012225232B2 (en) | 2011-03-09 | 2016-05-12 | Richard G. Pestell | Prostate cancer cell lines, gene signatures and uses thereof |
| CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| JP6518585B2 (ja) | 2012-05-14 | 2019-05-22 | リチャード ジー． ペステル | がんの治療のためのｃｃｒ５の修飾薬の使用 |
| PL4512390T1 (pl) | 2012-06-01 | 2025-09-01 | Ferring B.V. | Wytwarzanie degareliksu |
| NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| WO2014186608A1 (en) * | 2013-05-15 | 2014-11-20 | Adverse Events, Inc. | System and method for surveillance and evaluation of safety risks associated with medical interventions |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| AU2016261770B2 (en) * | 2015-05-12 | 2022-06-02 | Drexel University | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same |
| CN110248661A (zh) | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| BR112019014192A2 (pt) * | 2017-01-30 | 2020-02-11 | Antev Limited | Composição compreendendo pelo menos um antagonista de gnrh |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| EP3829584A4 (en) * | 2018-08-01 | 2022-06-08 | Abbvie Inc. | DOSAGE SCHEDULES FOR ELAGOLIX |
| RU2731002C1 (ru) * | 2019-10-22 | 2020-08-26 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения рака предстательной железы |
| CN116407494B (zh) * | 2023-03-02 | 2024-07-09 | 山东大学齐鲁医院 | 一种醋酸地加瑞克注射液及其制备方法、用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| ZA735680B (en) * | 1972-09-21 | 1974-07-31 | Hoffmann La Roche | Polypeptides |
| US4072668A (en) | 1973-11-06 | 1978-02-07 | The Salk Institute For Biological Studies | LH-RH Analogs |
| DE2862341D1 (en) | 1977-12-26 | 1983-11-24 | Ihara Chemical Ind Co | Process for producing aromatic monocarboxylic acid |
| US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| DE69214818T2 (de) | 1991-04-25 | 1997-02-27 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten |
| EP0556034B2 (en) | 1992-02-12 | 2004-07-21 | Daikyo Gomu Seiko Ltd. | A medical instrument |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| DE4305225A1 (de) * | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Herstellverfahren für Cetrorelix Lyophilisat |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| JP3688381B2 (ja) | 1995-03-10 | 2005-08-24 | 株式会社東芝 | 光ディスク原盤露光装置 |
| US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| US5710246A (en) | 1996-03-19 | 1998-01-20 | Abbott Laboratories | Process for intermediates for the synthesis of LHRH antagonists |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5977302A (en) | 1997-11-20 | 1999-11-02 | Ortho-Mcneil Pharmaceutical, Inc. | Liquid phase process for the preparation of GnRH peptides |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| CN1243543C (zh) | 1998-07-20 | 2006-03-01 | 派普泰克有限公司 | 生物植入物配方 |
| CN100500692C (zh) * | 2000-03-14 | 2009-06-17 | 赞塔里斯有限公司 | 新型lhrh拮抗剂,其制备方法和药物用途 |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20070015713A1 (en) | 2005-07-14 | 2007-01-18 | Voyager Pharmaceutical Corporation | Methods for treating prostate cancer |
| US20060234918A1 (en) * | 2001-12-19 | 2006-10-19 | Voyager Pharmaceutical Corporation | Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| SE0104463D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| BRPI0314546B8 (pt) | 2002-09-27 | 2021-05-25 | Zentaris Gmbh | composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit. |
| GB0223367D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Therapeutic treatment |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2006069779A1 (en) | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| ES2589322T3 (es) | 2008-02-11 | 2016-11-11 | Safety Syringes, Inc. | Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución |
| WO2010121835A1 (en) | 2009-04-24 | 2010-10-28 | Polypeptide Laboratories A/S | Method for the manufacture of degarelix |
| MX2011011431A (es) | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2011066386A1 (en) | 2009-11-25 | 2011-06-03 | Novetide, Ltd. | Process for production of degarelix |
| IT1399892B1 (it) | 2010-03-15 | 2013-05-09 | Spi Tecno Srl | Sistema per l illuminazione pubblica |
| ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| CN102204889B (zh) | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| KR20140063602A (ko) | 2011-07-15 | 2014-05-27 | 훼링 비.브이. | 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법 |
| PL4512390T1 (pl) | 2012-06-01 | 2025-09-01 | Ferring B.V. | Wytwarzanie degareliksu |
-
2009
- 2009-02-09 TW TW098104073A patent/TWI539959B/zh active
- 2009-02-09 TW TW098104075A patent/TWI442932B/zh active
- 2009-02-09 JO JOP/2009/0061A patent/JOP20090061B1/ar active
- 2009-02-10 PL PL12165896T patent/PL2505204T3/pl unknown
- 2009-02-10 KR KR1020227000962A patent/KR20220009504A/ko not_active Ceased
- 2009-02-10 SI SI200930942T patent/SI2249859T1/sl unknown
- 2009-02-10 CN CN2009801127793A patent/CN101998861A/zh active Pending
- 2009-02-10 PT PT131684045T patent/PT2650012E/pt unknown
- 2009-02-10 MX MX2010008817A patent/MX2010008817A/es active IP Right Grant
- 2009-02-10 DK DK12165896T patent/DK2505204T3/da active
- 2009-02-10 EP EP13168404.5A patent/EP2650012B1/en not_active Revoked
- 2009-02-10 RU RU2010133481/15A patent/RU2504393C2/ru active
- 2009-02-10 RU RU2010133480/15A patent/RU2504394C2/ru active
- 2009-02-10 EA EA200901074A patent/EA017582B1/ru not_active IP Right Cessation
- 2009-02-10 KR KR1020107020035A patent/KR101542480B1/ko active Active
- 2009-02-10 EP EP09709538A patent/EP2249858A1/en not_active Ceased
- 2009-02-10 MX MX2010008816A patent/MX2010008816A/es active IP Right Grant
- 2009-02-10 CN CN200980104713XA patent/CN101939020B/zh not_active Ceased
- 2009-02-10 PT PT97113906T patent/PT2249859E/pt unknown
- 2009-02-10 NZ NZ587057A patent/NZ587057A/xx unknown
- 2009-02-10 DK DK09711390.6T patent/DK2249859T3/da active
- 2009-02-10 HR HRP20140665AT patent/HRP20140665T1/hr unknown
- 2009-02-10 SI SI200931181T patent/SI2650012T1/sl unknown
- 2009-02-10 ES ES12165896.7T patent/ES2532709T3/es active Active
- 2009-02-10 DK DK13168404.5T patent/DK2650012T3/da active
- 2009-02-10 KR KR1020187030959A patent/KR20180118830A/ko not_active Ceased
- 2009-02-10 US US12/368,935 patent/US20090203623A1/en not_active Abandoned
- 2009-02-10 KR KR1020107020036A patent/KR20100123714A/ko not_active Ceased
- 2009-02-10 WO PCT/IB2009/000370 patent/WO2009101533A1/en not_active Ceased
- 2009-02-10 JP JP2010545575A patent/JP5924866B2/ja active Active
- 2009-02-10 CA CA2714445A patent/CA2714445C/en not_active Expired - Fee Related
- 2009-02-10 US US12/368,713 patent/US8841081B2/en active Active
- 2009-02-10 CN CN201710169651.7A patent/CN107412726A/zh active Pending
- 2009-02-10 EP EP18151844.0A patent/EP3360565A1/en active Pending
- 2009-02-10 KR KR1020257005826A patent/KR20250028541A/ko active Pending
- 2009-02-10 NZ NZ587088A patent/NZ587088A/xx unknown
- 2009-02-10 WO PCT/IB2009/000350 patent/WO2009101530A1/en not_active Ceased
- 2009-02-10 PT PT12165896T patent/PT2505204E/pt unknown
- 2009-02-10 CA CA2714444A patent/CA2714444A1/en active Pending
- 2009-02-10 EP EP09711390.6A patent/EP2249859B1/en not_active Revoked
- 2009-02-10 CN CN201410247166.3A patent/CN103990107A/zh active Pending
- 2009-02-10 KR KR1020237019555A patent/KR20230088848A/ko not_active Ceased
- 2009-02-10 KR KR1020157020657A patent/KR20150091543A/ko not_active Ceased
- 2009-02-10 PL PL09711390T patent/PL2249859T3/pl unknown
- 2009-02-10 BR BRPI0908127-5A patent/BRPI0908127A2/pt not_active Application Discontinuation
- 2009-02-10 AU AU2009213751A patent/AU2009213751B2/en active Active
- 2009-02-10 JP JP2010545576A patent/JP5876652B2/ja active Active
- 2009-02-10 EA EA201300742A patent/EA026521B1/ru not_active IP Right Cessation
- 2009-02-10 NZ NZ603932A patent/NZ603932A/en unknown
- 2009-02-10 BR BRPI0908129-1A patent/BRPI0908129A2/pt not_active Application Discontinuation
- 2009-02-10 KR KR1020147030003A patent/KR20140130757A/ko not_active Ceased
- 2009-02-10 PL PL13168404T patent/PL2650012T3/pl unknown
- 2009-02-10 AU AU2009213748A patent/AU2009213748B9/en active Active
- 2009-02-10 NZ NZ603958A patent/NZ603958A/xx unknown
- 2009-02-10 EP EP23174353.5A patent/EP4257197A3/en active Pending
- 2009-02-10 EP EP12165896.7A patent/EP2505204B1/en not_active Revoked
- 2009-02-10 EA EA201300741A patent/EA036695B1/ru not_active IP Right Cessation
- 2009-02-10 EA EA200901075A patent/EA020543B1/ru unknown
- 2009-02-10 ES ES13168404.5T patent/ES2540235T3/es active Active
- 2009-02-10 SI SI200931138T patent/SI2505204T1/sl unknown
- 2009-02-10 ES ES09711390.6T patent/ES2479441T3/es active Active
- 2009-02-10 EP EP14170557.4A patent/EP2799085A1/en not_active Ceased
- 2009-02-10 CA CA3235099A patent/CA3235099A1/en active Pending
-
2010
- 2010-07-29 IL IL207295A patent/IL207295A/en active IP Right Grant
- 2010-08-04 IL IL207400A patent/IL207400A/en active IP Right Grant
- 2010-08-10 ZA ZA2010/05697A patent/ZA201005697B/en unknown
- 2010-12-09 HK HK14111736.0A patent/HK1198243A1/en unknown
-
2012
- 2012-04-27 US US13/458,330 patent/US9415085B2/en active Active
- 2012-11-19 IL IL223124A patent/IL223124A0/en unknown
-
2013
- 2013-12-24 US US14/139,922 patent/US9579359B2/en active Active
-
2014
- 2014-03-14 JP JP2014051197A patent/JP6189234B2/ja active Active
- 2014-04-22 JP JP2014087895A patent/JP6254042B2/ja active Active
- 2014-07-18 CY CY20141100542T patent/CY1115561T1/el unknown
- 2014-08-08 US US14/454,825 patent/US9877999B2/en active Active
-
2015
- 2015-02-13 CY CY20151100155T patent/CY1116341T1/el unknown
- 2015-03-16 HR HRP20150290AT patent/HRP20150290T1/hr unknown
- 2015-05-14 CY CY20151100434T patent/CY1116289T1/el unknown
- 2015-06-12 HR HRP20150633TT patent/HRP20150633T1/hr unknown
-
2016
- 2016-05-11 JP JP2016095555A patent/JP2016193910A/ja active Pending
- 2016-05-18 JP JP2016099437A patent/JP2016216455A/ja active Pending
- 2016-07-08 US US15/205,108 patent/US10695398B2/en active Active
-
2017
- 2017-01-13 US US15/405,552 patent/US10729739B2/en active Active
- 2017-09-27 JP JP2017185676A patent/JP6618967B2/ja active Active
- 2017-12-18 US US15/845,391 patent/US20190167755A1/en not_active Abandoned
-
2020
- 2020-04-17 US US16/851,179 patent/US10973870B2/en active Active
- 2020-05-21 US US16/880,608 patent/US11766468B2/en active Active
-
2021
- 2021-03-12 US US17/199,733 patent/US12533387B2/en active Active
-
2022
- 2022-03-31 US US17/710,899 patent/US11826397B2/en active Active
- 2022-03-31 US US17/710,905 patent/US20220218783A1/en not_active Abandoned
- 2022-03-31 US US17/710,889 patent/US20220218782A1/en not_active Abandoned
- 2022-05-31 US US17/829,134 patent/US20220323538A1/en not_active Abandoned
- 2022-07-07 JP JP2022109616A patent/JP7400029B2/ja active Active
- 2022-09-08 JP JP2022142833A patent/JP2022184898A/ja active Pending
-
2023
- 2023-12-06 JP JP2023206150A patent/JP2024028869A/ja active Pending
-
2024
- 2024-05-30 US US18/679,184 patent/US20250134948A1/en active Pending
- 2024-05-31 US US18/680,542 patent/US12514898B2/en active Active
-
2025
- 2025-06-24 JP JP2025106071A patent/JP2025160167A/ja active Pending
- 2025-11-14 JP JP2025194876A patent/JP2026027448A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI539959B (zh) | 治療轉移階段攝護腺癌的方法 | |
| JP7186748B2 (ja) | 転移期前立腺癌を治療する方法 | |
| HK1190912B (en) | Treatment of metastatic stage prostate cancer with degarelix | |
| KR20240037954A (ko) | 니라파립을 이용한 전이성 거세-저항성 전립선암의 치료 |